Thought Leadership
Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 124 posts
May 20, 2020 | Podcasts
Speaking of Access: The Management of Tumor-Agnostic Therapies
Andrew Gould asks our US payer panel for their expert perspectives surrounding the management of tumor-agnostic therapies.
![THE USE OF INTEGRATED DELIVERY NETWORKS [FINAL POSTER] WEB IMAGE](https://cbpartners.s3.eu-west-1.amazonaws.com/wp-content/uploads/2020/06/11121205/THE-USE-OF-INTEGRATED-DELIVERY-NETWORKS-FINAL-POSTER-WEB-IMAGE-scaled.png)
May 18, 2020 | Research posters
ISPOR Annual 2020: The Use of Integrated Delivery Networks as Pioneers for Manufacturer HEOR Program / Study Success
A research poster identifying the impact of utilizing Integrated Delivery Networks and their in-house resources in fulfilling HEOR program requirements.
May 18, 2020 | Research posters
ISPOR Annual 2020: Re-Submissions with RWE: Can They Help Change Your Benefit Rating?
A research poster that aims to understand the role of RWE in re-submissions and determine if this type of evidence can help to improve HTA outcomes when products are re-assessed by the Haute Autorité de Santé (HAS) in France and Gemeinsamer Bundesausschuss (G-BA) in Germany.
May 18, 2020 | Research posters
ISPOR Annual 2020: The Resultant Impact of HEOR Data on US Payer Formulary Coverage
A research poster identifying instances where manufacturer HEOR data and/or pharmacoeconomic models either influenced positive changes, or had limited tangible impact on resultant US payer coverage decisions.
May 18, 2020 | Research posters
ISPOR Annual 2020: Collaborative Approaches to Attain Healthcare Sustainability in Latin America
This research poster aims to identify hurdles to achieving healthcare sustainability in LA, review approaches taken by policy makers to control healthcare budgets and propose actionable solutions to attain sustainability that mutually benefit healthcare systems and industry.